Cancer Treatment Reviews
Volume 37, Issue 2 , Pages 120-126 , April 2011

Cancer of unknown primary patients with midline nodal distribution: Midway between poor and favourable prognosis?

Received 27 April 2010 ,Revised 27 June 2010 ,Accepted 29 June 2010.

References 

  1. Pavlidis N, Briasoulis E, Hainsworth J, Greco FA. Diagnostic and therapeutic management of cancer of an unknown primary. Eur J Cancer. 2003;39:1990–2005
  2. Pentheroudakis G, Briasoulis E, Karavassilis V, Fountzilas G, Xeros N, et al. Chemotherapy for patients with two favourable subsets of unknown primary carcinoma: active, but how effective?. Acta Oncol. 2005;44:155–160
  3. Randen M, Rutqvist LE, Johansson H. Cancer patients without a known primary: incidence and survival trends in Sweden 1960–2007. Acta Oncol. 2009;48(6):915–920
  4. Lazaridis G, Pentheroudakis G, Fountzilas G, Pavlidis N. Liver metastases from cancer of unknown primary (CUPL): a retrospective analysis of presentation, management and prognosis in 49 patients and systematic review of the literature. Cancer Treat Rev. 2008;34:693–700
  5. Adenis A, Ferté C, Penel N. Phase II trials in patients with carcinoma of unknown primary: a pooled data analysis. Invest New Drugs. 2010 Apr;28(2):178–184
  6. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer: I. The value of histologic grade in breast cancer—experience from a large study with long-term follow-up. Histopathology. 1991;19:403–410
  7. Greco A, Vaughn W, Hainsworth J. Advanced poorly differentiated carcinoma of unknown primary site: recognition of a treatable syndrome. Ann Inter Med. 1986;104:547–553
  8. Pavlidis N, Kosmidis P, Skarlos D, Briaosulis E, Beer M, et al. Subsets of tumors responsive to cisplatin or carboplatin combinations in patients with carcinoma of unknown primary site. Ann Oncol. 1992;3:631–634
  9. Hainsworth J, Johnson D, Greco A. Cisplatin-based combination chemotherapy in the treatment of poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown primary site: results of a 12-year experience. J Clin Oncol. 1992;10(6):912–922
  10. Abbruzzese J, Abbruzzese M, Hess K, Raber M, Lenzi R, et al. Unknown primary carcinoma: natural history and prognostic factors in 657 consecutive patients. J Clin Oncol. 1994;12(6):1272–1280
  11. Van der Gaast A, Verweij J, Planting AST, Hop WCJ, Stater G. Simple prognostic model to predict survival in patients with undifferentiated carcinoma of unknown primary site. J Clin Oncol. 1995;13(7):1720–1725
  12. Lenzi R, Hess K, Abbruzzese M, Raber M, Ordonez R, et al. Poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown origin: favorable subsets of patients unknown-primary carcinoma?. J Clin Oncol. 1997;15(5):2056–2066
  13. Briasoulis E, Tsavaris N, Fountzilas G, Athanasiadis A, Kosmidis P, et al. Combination regimen with carboplatin, epirubicin and etoposide in metastatic carcinomas on unknown primary site: a Hellenic Co-operative Oncology Group phase II study. Oncology. 1998;55:426–430
  14. Briasoulis E, Kalofonos H, Bafaloukos D, Samantas E, Fountzilas G, et al. Carboplatin plus paclitaxel in unknown primary carcinoma: a phase II Hellenic Co-operative Oncology Group study. J Clin Oncol. 2000;18(17):3101–3107
  15. Greco A, Burris H, Litchy S, Barton J, Bradof J, et al. Gemcitabine, carboplatin and paclitaxel for patients with carcinoma of unknown primary site: a Minnie Pearl Cancer Network study. J Clin Oncol. 2002;20(6):1651–1656
  16. Pentheroudakis G, Briasoulis E, Kalofonos H, Fountzilas G, Economopoulos T, et al. Docetaxel and carboplatin combination chemotherapy as outpatient palliative therapy in carcinoma on unknown primary: a multicentre Hellenic Co-operative Oncology Group study. Acta Oncol. 2008;47:1148–1155
  17. Hartmann JT, Nichols CR, Droz JP, Horwich A, Gerl A, et al. Prognostic variables for response and outcome in patients with extragonadal germ-cell tumors. Ann Oncol. 2002;13:1017–1028
  18. Pectasides D, Aravantinos G, Visvikis A, Bakoyiannis Ch, Halikia A, et al. Platinum-based chemotherapy of primary extragonadal germ cell tumors: Hellenic Co-operative Oncology Group experience. Oncology. 1999;57:1–9
  19. Shah T, Srirajaskanthan R, Bhogal M, Toubanakis C, Meyer T, Noonan A, et al. a-Fetoprotein and human chorionic gonadotrophin-b as prognostic markers in neuroendocrine tumor patients. Br J Cancer. 2008;99:72–77
  20. Lloyd RV. Practical markers used in the differential diagnosis of endocrine tumors. Endocr Pathol. 2003;14:293–301
  21. Suster S, Moran CA. Neuroendocrine neoplasms of the mediastinum. Am J Clin Pathol. 2001;115(Suppl.):S17–S27(Review)
  22. Currow DC, Findlay M, Cox K, Harnett PR. Elevated germ cell markers in carcinoma of uncertain primary site do not predict response to platinum based chemotherapy. Eur J Cancer. 1996;32A(13):2357–2359
  23. Varadhachary GR, Talantov D, Raber MN, Meng C, Hess KR, Jatkoe T, et al. Molecular profiling of carcinoma of unknown primary and correlation with clinical evaluation. J Clin Oncol. 2008;26(27):4442–4448
  24. Horlings HM, van Laar RK, Kerst JM, Helgason HH, Wesseling J, van der Hoeven JJ, et al. Gene expression profiling to identify the histogenetic origin of metastatic adenocarcinomas of unknown primary. J Clin Oncol. 2008;26(27):4435–4441

PII: S0305-7372(10)00108-8

doi: 10.1016/j.ctrv.2010.06.003

Cancer Treatment Reviews
Volume 37, Issue 2 , Pages 120-126 , April 2011

Article Tools

* Image Usage & Resolution